Published in Managed Care Business Week, June 22nd, 2004
"The patient had recurrent infections due to relative neutropenia, secondary to bone marrow infiltration," noted Y.A. Mourad and coauthors at the American University in Beirut. "After treatment with monoclonal anti-CD20 antibodies (rituximab) 375 mg/m2 weekly for 4 weeks, complete remission was obtained."
"It was documented by normalization of peripheral blood counts, disappearance of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.